Skip to main content

Table 2 Presence or absence of adverse events

From: A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Adverse Events (N = 33)

Sequential

(n = 11)

Up-front combination

(n = 22)

P-value

Diarrhea

8 (72.7%)

14 (63.6%)

0.602

Dermatitis

11 (100%)

22 (100%)

--

Paronychia

7 (63.6%)

13 (59.1%)

0.801

Nausea & Vomiting

1 (9.1%)

0 (0%)

0.151

Mucositis

0 (0%)

0 (0%)

--

Hepatitis

0 (0%)

0 (0%)

--

Hemorrhagic events

0 (0%)

0 (0%)

--

Renal dysfunction

0 (0%)

0 (0%)

--